Clinical trials: Hormone Disturbance
Diabetes Mellitus, Type 1
A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 1 Diabetes Mellitus
The purpose of this study is to evaluate a new formulation of insulin lispro, LY900014, which is a drug that lowers blood sugar.
- Trial name
- NCT03341299
- Testing
- LY900014, Insulin Lispro
- Where
- 2 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Ovarian Cancer, Fallopian Tube Cancer
Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers
The purpose of this study is to evaluate the clinical safety and toxicity of intravenous bevacizumab (Days 1 and 15 of a 28 day cycle) in combination with weekly topotecan (Days 1, 8, 15 of a 28 day cycle) in patients with…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT00343044
- Testing
- Topotecan, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Benaroya Research Institute
Diabetes Mellitus, Type 2
Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)
The aim of the study is to investigate the longterm impact on cardiovascular morbidity, mortality and renal function of treatment with linagliptin in a selected population of patients with Type 2 diabetes mellitus (T2DM) and to…
- Trial name
- NCT01897532
- Testing
- Linagliptin
- Where
- 649 sites in United States, Argentina and 25 more
- Volunteers
- 6,991 people
- Sponsor
- Boehringer Ingelheim
Pancreas Cancer, Pancreas Disease
Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula Following Distal Pancreatectomy
Despite improvements and advances in pancreas surgery, about 30-35% of patients who have pancreas surgery develop a type of complication called a pancreatic fistula.
- Conditions
- Pancreas Cancer, Pancreas Disease, Pancreas Adenocarcinoma, Pancreas; Fistula
- Trial name
- PATCH-DP (NCT03410914)
- Testing
- Hemopatch
- Where
- 7 sites in Canada
- Volunteers
- 52 people
- Sponsor
- Sunnybrook Health Sciences Centre
Painful Diabetic Neuropathy, Diabetes
A Safety Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Painful Diabetic Neuropathy
Study CLO-311 is a multicenter, open-label, single-arm study to assess the long-term use of Clonidine Gel in the treatment of pain associated with PDN.
- Trial name
- NCT02355158
- Testing
- clonidine hydrochloride topical gel, 0.1%
- Where
- 20 sites in United States
- Volunteers
- 197 people
- Sponsor
- BioDelivery Sciences International
Obesity
To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes
This study is the first administration of GSK2890457 in humans. The study will be conducted in 3 parts: - Part A (conducted at a single investigative site) will determine the safety and tolerability of GSK2890457 alone in healthy…
- Trial name
- NCT01725126
- Testing
- GSK2890457, Metformin, Liraglutide
- Where
- 3 sites in United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Obesity
Study of the Gut Hormone Analogue Y14 in Adult Subjects
A randomised, placebo controlled Phase I study to investigate investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of Y14 in adult subjects.
- Trial name
- NCT03673111
- Testing
- Y14
- Where
- United Kingdom
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Type 1 Diabetes
Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia
The main purpose of the study is to determine the effects of 16 weeks of adjunctive pramlintide or exenatide use on glycemic control in Type 1 Diabetes.
- Trial name
- NCT01269047
- Testing
- Pramlintide, Exenatide, Insulin
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Albert Einstein College of Medicine
Ovarian Neoplasms
Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
Comparison of Nexavar with a placebo as maintenance therapy for patients with advanced Ovarian or primary Peritoneal cancers in complete remission following surgery and one regimen of chemotherapy.
- Trial name
- NCT00791778
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 59 sites in United States, Belgium and 12 more
- Volunteers
- 246 people
- Sponsor
- Bayer
Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy
Phase II trial to study the effectiveness of ixabepilone in treating patients who have recurrent or persistent ovarian epithelial or primary peritoneal cancer that has not responded to previous chemotherapy.
- Trial name
- NCT00025155
- Testing
- ixabepilone
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Foot Ulcers
DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes
A randomized versus placebo trial designed to evaluate the clinical and humoral effects of 4 months of vildagliptin on healing of chronic ulcers in type 2 diabetes.
- Trial name
- NCT01472432
- Testing
- vildagliptin
- Where
- Italy
- Volunteers
- 106 people
- Sponsor
- University of Campania Luigi Vanvitelli
Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection
Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection
This is an open-label study evaluating the safety and efficacy of CP101 treatment in 1) Subjects in CDI-001 who had a CDI recurrence within 8 weeks of receiving CP101 or placebo; OR 2) adults with recurrent CDI who are eligible…
- Conditions
- Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection, C. Diff, CDI
- Trial name
- PRISM-EXT (NCT03497806)
- Testing
- CP101
- Where
- 57 sites in United States, Canada
- Volunteers
- 132 people
- Sponsor
- Finch Research and Development LLC.
Solid Tumors
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications.
- Trial name
- NCT01772004
- Testing
- Avelumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 1,756 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Pancreatic Cancer
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
This is a Phase 2 multicenter, open-label, non-randomized study to examine the safety and effectiveness of BPM31510 administered over 144-hours (two 72-hour 110mg/Kg doses) continuous intravenous (IV) infusion in combination with…
- Trial name
- NCT02650804
- Testing
- BPM31510 Nanosuspension Injection, Gemcitabine
- Where
- 12 sites in United States, United Kingdom
- Volunteers
- 45 people
- Sponsor
- BPGbio
Diabetes Mellitus, Type 2
A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus
The aim of this study is to monitor safety and efficacy of treatment with linagliptin in Korean patients with type 2 diabetes mellitus in routine clinical settings.
- Trial name
- NCT01707147
- Testing
- Trajenta tablet
- Where
- South Korea
- Volunteers
- 3,219 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to basal insulin with or without sulfonylurea, over a period of 24 weeks of treatment.
- Trial name
- GETGOAL-L-ASIA (NCT00866658)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Sulfonylurea
- Where
- 4 sites in Japan, Philippines and 2 more
- Volunteers
- 311 people
- Sponsor
- Sanofi
Hypogonadism, Male
Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021).
Multicenter, open-label, one treatment study evaluating the efficacy of LPCN 1021 in adult hypogonadal male subjects.
- Trial name
- DV (NCT03242590)
- Testing
- LPCN 1021
- Volunteers
- 95 people
- Sponsor
- Lipocine Inc.
Diabetes Mellitus, Type 1
GPR119 Agonist for Hypoglycemia in Type 1 Diabetes
The purpose of this study is to test if a specific research medication could increase the response to low blood glucose in people with type 1 diabetes.
- Trial name
- PHROG (NCT04432090)
- Testing
- Study Medication (MBX-2982), No medication for this group
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Type 2 Diabetes
My Diabetes, My Community
Older adults with diabetes are a highly vulnerable population that suffers the highest rates of cardiovascular and microvascular complications as well as adverse drug events such as hypoglycemia.
- Trial name
- NCT04970810
- Testing
- My Diabetes Goal, My Diabetes Goal + CommunityRx
- Where
- United States
- Volunteers
- 512 people
- Sponsor
- University of Chicago
Type 2 Diabetes Mellitus
MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)
The clinical study determines the safety and efficacy of MK0431 in patients with type 2 diabetes mellitus who have inadequate glycemic control on pioglitazone as monotherapy.
- Trial name
- NCT00372060
- Testing
- sitagliptin phosphate, Comparator: sitagliptin phosphate (MK0431), Comparator: pioglitazone
- Volunteers
- 134 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.